China News Agency, Beijing, January 14th: The official said that the current peak of fever clinics has passed. A new crown treatment drug has completed its first launch in the Chinese market
China News Agency reporter Li Chun
"The peak of fever clinics has passed", "the national emergency peak has passed", "normal outpatient clinics are gradually recovering"... The above information was released at the press conference of the Joint Prevention and Control Mechanism of the State Council of China on the 14th.
And just the day before, the new crown virus oral drug Monogravir Capsules completed its first launch in the Chinese market and has been delivered to medical institutions.
Chinese officials also stated that they are studying strengthening the provision of small-molecule antiviral drugs in grassroots health institutions.
The peak of fever clinics has passed
Many places have previously announced that the peak of this round of new crown infections has passed.
After the implementation of "Class B and B control", what is the trend of the number of fever clinics and outpatient and emergency visits in China?
When answering a question from a reporter from China News Agency at the press conference of the Joint Prevention and Control Mechanism of the State Council of China on the 14th, Jiao Yahui, director of the Department of Medical Affairs of the National Health Commission, said that currently all provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps have fever clinics and consultation rooms. The number of outpatients showed an overall downward trend after reaching the peak, and the rural areas also showed a downward trend, with urban and rural areas converging.
The detection rate of positive COVID-19 infections in fever clinics has also continued to decline.
Jiao Yahui said that this trend shows that the peak of fever outpatient visits has passed.
She also said that the emergency department also showed a continuous downward trend after reaching the peak, and the data showed that the national emergency department peak has passed.
The daily consultation volume of general outpatient clinics continues to increase, and normal diagnosis and treatment are gradually recovering.
On the other hand, many places have recently released information stating that around the Spring Festival, there may be a second wave of small peak infections.
The "Shaoxing Release" WeChat official account previously posted that with the arrival of the holidays, the flow of people is relatively intensive, and rural areas are ushering in a wave of people returning to their hometowns. There may be a wave of small peaks of infection around the Spring Festival.
Cai Maorong, Secretary of the Party Committee of the Zhangzhou Center for Disease Control and Prevention in Fujian Province, said in an interview that the city is expected to usher in a second wave of small peak infections before the Spring Festival.
Wang Chunting, head of the medical treatment expert team of the Shandong Provincial New Crown Epidemic Management Leading Group, also said earlier this month that the second wave of infection peaks in Jinan City will occur during the Spring Festival after the start of the Spring Festival travel rush on January 10.
Number of critically ill patients in hospital remains high
The treatment of critically ill patients is the top priority of China's epidemic prevention and control work.
At present, the focus of prevention and control has shifted to "protecting health and preventing severe illness". What is the situation of the treatment of severe new crown cases across the country?
Jiao Yahui said that the monitoring data showed that two weeks after the peak of fever outpatient visits, the number of severe patients with new crown positive in the hospital also reached its peak, and then showed a slow downward trend.
"The number of critically ill patients currently in hospital is still at a high level."
According to reports, on January 5 this year, the number of critically ill patients with COVID-19 in hospital in China peaked at 128,000, and then continued to fluctuate and decline.
As of January 12, the number of positive severe patients in the hospital fell back to 105,000.
Among the critically ill patients with COVID-19 positive in the hospital on January 12, there were 97,000 people with severe underlying diseases combined with COVID-19 infection, accounting for 92.8%; 7,357 severe patients with COVID-19 infection, accounting for 7%.
Rural areas are key areas for epidemic prevention and control.
From the perspective of medical treatment, the ability to treat severe cases of COVID-19 in rural areas needs to be further improved.
Jiao Yahui also mentioned that it is necessary to give full play to the leading role of county hospitals, make preparations including beds, equipment, facilities, and personnel, and improve the ability to treat severe cases; Establish a one-to-one support relationship with county hospitals; establish a support and referral mechanism and a green channel between cities and counties to ensure that critically ill patients in rural areas can be referred and admitted in a timely manner.
Monogravir debuts in Chinese market
According to reports, on the afternoon of January 13, a truck loaded with monogravir capsules, a new coronavirus treatment drug, was sent from Shanghai Waigaoqiao Free Trade Zone to the whole country.
At 23:58 on the same day, Sinopharm Holdings Guangzhou Company and Sinopharm Holdings Beijing Company delivered the drugs to medical institutions respectively, completing the first order delivery in the country.
On December 29, 2022, the State Drug Administration of China conditionally approved the import registration of Merck's new coronavirus treatment drug, Monogravir Capsules.
The drug is an oral small-molecule novel coronavirus treatment drug for the treatment of mild to moderate novel coronavirus infection in adults with high risk factors for developing severe disease.
China recently announced the tenth edition of the new crown diagnosis and treatment plan, and monogravir capsules were also included.
Wang Guiqiang, director of the Department of Infectious Diseases at Peking University First Hospital, said recently that antiviral therapy is an important part of comprehensive treatment, and small molecule drugs are convenient to take orally and can be used in community family clinics.
It is given priority to the high-risk groups of severe illness, that is, the elderly, people with underlying diseases, and those who have not been vaccinated, which can reduce the risk of severe illness.
Wang Guiqiang also said that the small-molecule novel coronavirus treatment drug developed in China is undergoing intensive clinical trials. If the clinical results are effective, it is expected to be approved for marketing as soon as possible.
At the press conference on January 14, Jiao Yahui also said that he is currently studying to strengthen the provision of small-molecule antiviral drugs in grassroots health institutions to further improve the medical treatment capabilities of grassroots health institutions.